Search

Displaying results 6731 - 6740 of 9333 in total
  1. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    The product is intended for basal insulin treatment of diabetes mellitus.

  2. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.

  3. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  4. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine. … It is being devloped by Intercell AG for the treatment of hepatitis C.

  5. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  6. Drug

    (1R,2S)-2-Phenylcyclopropanaminium

    go.drugbank.com/drugs/DB02665
    Experimental

    A propylamine formed from the cyclization of the side chain of amphetamine. … This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders.

  7. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    It is designed to combat colds caused by rhinovirus.

  8. Drug

    ATA-100

    go.drugbank.com/drugs/DB18329
    Investigational

    ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a

  9. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  10. Drug

    Aminocandin

    go.drugbank.com/drugs/DB05128
    Experimental

    Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.